BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Pharm Country

  Early Warnings of Monkeypox Ignored Prior to Unprecedented Outbreak

  Warnings of Monkeypox went unheeded as scientists around the world began to uncover clues about the disease’s origin. Here are the latest updates on the monkeypox virus.

  May 26, 2022

   · 

  4 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Acer Therapeutics Readies for FDA Ruling on UCDs Drug

  On June 5, the FDA is expected to decide the fate of Acer Therapeutics’ experimental treatment for Urea Cycle Disorders (UCDs), ACER-001. CEO Chris Schelling spoke with BioSpace.

  May 26, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Business

  BioSpace Movers & Shakers: New Appointments for Maraganore, Afeyan

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

  May 26, 2022

   · 

  7 min read

   · 

  Alex Keown
• 

  Business

  Flagship-Backed ProFound Therapeutics Scores $75M to Explore Undiscovered Proteins

  Flagship Pioneering introduced ProFound Therapeutics, a new company that leverages previously undiscovered human proteins to develop treatments for many diseases.

  May 26, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  BioCapital

  Novavax Readies COVID-19 Vaccine for FDA Advisory Committee Meeting

  The FDA’s Vaccines and Related Biological Products Advisory Committee is set to review clinical data on June 7 and potentially suggest approval of NVX-CoV2373.

  May 26, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Pfizer’s NASH Treatment Lands FDA Fast Track Designation

  Pfizer announced the FDA has granted its combinatorial therapeutic ervogastat/clesacostat Fast Track Designation that is intended for the treatment of NASH with liver fibrosis.

  May 26, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Exploring the Causal Connection Between COVID-19 and Diabetes

  Research is emerging showing a causal link between COVID-19 and diabetes. Dr. Brian Fertig, M.D., founder and president of the Diabetes & Osteoporosis Center in New Jersey, spoke with BioSpace.

  May 26, 2022

   · 

  4 min read

   · 

  Abbey Glasure
• 

  Research Roundup: New Insight into Gene Mutations Associated with Autism, Schizophrenia

  Researchers have linked gene mutations with certain neurological disorders, and new research has tied some mechanisms together. Also, insight into how to prevent or delay Type 2 diabetes.

  May 26, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Once Hopeful Critical COVID-19 Treatment Reaches Futility

  ZYESAMI, (aviptadil), being assessed by NRx Pharmaceuticals, failed a review conducted by the Data Safety and Monitoring Board (DSMB), with the board recommending that arm of the trial cease.

  May 26, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh
• 

  Policy

  Enochian Biosciences Cofounder Charged in Murder-for-Hire Scheme

  Shares of Enochian Biosciences plunged more than 36% after the Justice Department announced company cofounder Serhat Gumrukçu was arrested in a sordid 2018 murder-for-hire scheme.

  May 26, 2022

   · 

  3 min read

   · 

  Alex Keown